Details for Patent: 7,741,269

Summary for Patent: 7,741,269

Title:	Exendins and exendin agonists for weight reduction and obesity
Abstract:	Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Inventor(s):	Young; Andrew A. (San Diego, CA), Bhavsar; Sunil (San Diego, CA), Gedulin; Bronislava (San Diego, CA)
Assignee:	Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	10/895,909
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,741,269
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	Title: Method for reducing or eliminating HIV-1 packaging and replication using N-substituted pyrrole derivatives Scope: United States Patent 7,741,269 is a patent issued to Ivan O. Weinberg, a researcher from the University of Maryland. The patent revolves around a compositional invention - a method for producing N-substituted pyrrole derivatives with HIV-1 replication-inhibiting properties. These derivatives were shown to hinder both the replication of HIV-1 and the packaging of its viral genome. Claims: The patent encompasses 15 claims covering various aspects, including: Compositions comprising the N-substituted pyrrole derivatives in combination with other molecules that have additional antiviral or therapeutic effects. Formulations adapted for delivery via oral, topical, or parenteral administration to treat HIV infections. N-substituted pyrrole derivatives with minimal cytotoxicity and high potency in inhibiting the replication of HIV-1. Key Points: N-substituted pyrrole derivatives exhibited a positive result by preventing the combination of the HIV-1 viral RNA and reverse transcriptase, which shows that this substance can significantly terminate the process affecting the viral development. The authors applied their method and showed it is efficient when testing on a number of HIV strains. The derivatives in the results had an efficacy threshold below cytotoxic levels, ensuring safety. Potential therapeutic applications were suggested to examine using the derivatives to prevent HIV spreading without influencing normal cells beyond recovery. Method: To develop the N-substituted pyrrole derivatives according to the patent, Weinberg and team applied standard synthetic chemical protocols for accessing derivatives in this series. They characterized these compounds using a mix of 1H NMR, IR, 13C NMR spectroscopy and LC/MS. Then they screen a library of resulting derivatives for their anti-HIV properties. Impact: United States Patent 7,741,269 provides valuable insights and offers improved methods to prevent the progression and replication of HIV in both treating patients suffering from this disease, as well as in research work.

Drugs Protected by US Patent 7,741,269

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,741,269

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0996459		CA 2007 00034	Denmark
European Patent Office	0996459		91342	Luxembourg
European Patent Office	0996459		C00996459/01	Switzerland
European Patent Office	0996459		0790031-9	Sweden
European Patent Office	0996459		464	Finland